A group of women posing for a photo across the river from Westminster, holding a large purple banner that reads "Make life extending drug ENHERTU available on the NHS now!"

Enhertu emergency

Enhertu is a drug that can help extend the life of certain people with incurable HER2-low secondary breast cancer. But it's been rejected for use on the NHS in England.

This means thousands of people will be denied access to a drug that could give them the hope of more time to live.

We’ve been working hard to get all parties to find a solution to make Enhertu available to the people who so desperately need it, across the UK.

Despite securing the Health Secretary’s intervention, which led to further talks between the NHS England and the drug companies, we’re devastated that NICE, NHS England, Daiichi Sankyo and AstraZeneca have failed to find a way forward.

We’re sorry that we haven’t yet brought about the result we all wanted to see. But you can still sign our petition to show NICE, NHS England, and the drug companies that Enhertu needs to be made available on the NHS, across the UK.

Frequently asked questions

  • What is trastuzumab deruxtecan (Enhertu)?

    Trastuzumab deruxtecan is a targeted (biological) therapy. Targeted therapies interfere with processes in cells that help cancer grow.

    Trastuzumab deruxtecan combines 2 drugs: 

    • A targeted therapy drug that’s very similar to trastuzumab (Herceptin) and works in the same way
    • A chemotherapy drug called deruxtecan or DXd 

    The drug is developed and commercialised by Daiichi Sankyo and AstraZenca.

  • What is HER2-low?

    HER2-low is a newly-classified subgroup of breast cancer previously considered HER2-negative.

    People with HER2-low secondary breast cancer have low levels of HER2-expression.

  • Who is eligible for Enhertu?

    Enhertu was assessed by NICE for treating HER2-low secondary or unresectable (cannot be removed by surgery) breast cancer in adults following:

    • Chemotherapy for secondary breast cancer
    • Or after a recurrence during chemotherapy for primary breast cancer or within 6 months after finishing chemotherapy

  • Why was Enhertu rejected for use on the NHS in England?

    In September 2023, Enhertu was provisionally rejected by the National Institute for Health and Care Excellence (NICE) for use on the NHS. There was a period of consultation about this decision which we responded to.

    In December, the NICE process was paused to enable the drug companies Daiichi Sankyo and AstraZeneca, and NHS England, to enter negotiations which we hoped would result in a deal that would make the treatment available on the NHS.

    Since September, we’ve met NICE, NHS England and the drug companies on numerous occasions, urging them all to work together to ensure this life-extending treatment could be made available on the NHS.

    But now we’ve received the devastating news that no deal has been made and NICE has not recommended this treatment for use on the NHS.

    NICE has said that the most likely cost-effectiveness estimates are above what NICE considers an acceptable use of NHS resources.

    Underlying all of this is another issue which we believe has played a part in this appraisal. 2 years ago, NICE made changes to the methods it uses to assess treatments and the end-life-modifier being replaced with a new severity modifier.

    A modifier is something that can affect NICE's decision-making.

    Broadly speaking, the end-of-life modifier gave additional weight to treatments that extended the lives of those living with an incurable disease, such as secondary breast cancer. The severity modifier gives additional weight to the most severe conditions.

    At the time, we raised concerns about the impact this change could have on some cancer drugs for people living with incurable cancer. We’re concerned about the impact this change has had on the NICE appraisal of Enhertu.

    Our concerns have been reiterated by the All-Party Parliamentary Group on Breast Cancer and the Health and Social Care Committee. Both wrote to NHS England, NICE and Daiichi Sankyo.

  • Is Enhertu available in Scotland, Wales or Northern Ireland?

    Wales and Northern Ireland usually follow drug decisions made in England.

    So the decision to not recommend Enhertu means people in Wales and Northern Ireland will likely miss out too.

    Enhertu was approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland in December 2023.

Sign our petition

Please sign and share our petition calling for a solution to make Enhertu available on the NHS. Help give these people back their hope.

Add your name

Find out more about our campaigns

  •  
  • Women posing for photos with placards and megaphones, in Westminster.

    Campaign with us

    We're campaigning get people affected by breast cancer the best treatment, services and care.

  • A group of volunteers, posing for photos in the gardens surrounding Westminster

    Campaign successes

    Thanks to you, our campaigns are making things better for people living with or affected by breast cancer. Learn about our recent successes.

  •  

Share this page